Trastuzumab pamirtecan

Highest phase reached
Phase 2
www.ebi.ac.uk
Drug type
Antibody drug conjugate
www.ebi.ac.uk

Listing at source
Listed
Highest phase reached
Phase 2
www.ebi.ac.uk

Drug type
Antibody drug conjugate
www.ebi.ac.uk
Drug name
Trastuzumab pamirtecan
www.ebi.ac.uk

  • bnt 323
  • BNT-323
  • db 1303
  • DB 1303 [WHO-DD]
  • db 1303 who dd
  • DB-1303
  • h gamma1 heavy chain humanized 1 449 vh homo sapiens ighv3 66 01 81 6 ighd ighj4 01 100 cdr imgt 8 8 13 26 33 51 58 97 109 1 120 homo sapiens ighg1 03v g1m3 g1m17 ng1m1 ch1 k120 ch3 e12 m14 ch1 r120 k 217 121 218 hinge 1 15 219 233 ch2 234 343 ch3 e12 359 m14 361 344 448 chs k2 del 449 121 449 223 214 disulfide with l kappa light chain humanized 1 214 v kappa homo sapiens igkv1 39 01 86 3 igkj1 01 100 cdr imgt 6 3 9 27 32 50 52 89 97 1 107 homo sapiens igkc 01 100 km3 a45 1 v101 c kappa a45 1 153 v101 191 108 214 dimer 229 229 232 232 bisdisulfide produced in a cell line from chinese hamster ovary cho cells derived from the cell line cho k1 glycoform alfa substituted at the sulfur atoms of l cysteinyl residues 223 229 232 214 223 229 232 and 214 with 3rs 1 7s 7 benzyl 1 1r 3r 3 1s 9s 9 ethyl 5 fluoro 9 hydroxy 4 methyl 10 13 dioxo 2 3 9 10 13 15 hexahydro 1h 12h benzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl carbamoyl cyclobutyl oxy 3 6 9 12 15 pentaoxo 2 5 8 11 14 pentaazaicosan 20 yl 2 5 dioxopyrrolidin 3 yl pamirtecan groups
  • H-gamma1 heavy chain humanized (1-449) [VH (Homo sapiens IGHV3-66*01 (81.6%) -(IGHD) -IGHJ4*01 (100%), CDR-IMGT [8.8.13] (26-33.51-58.97-109)) (1-120) -Homo sapiens IGHG1*03v, G1m3>G1m17, nG1m1 CH1 K120, CH3 E12, M14 (CH1 R120>K (217) (121-218), hinge 1-15 (219-233), CH2 (234-343), CH3 E12 (359), M14 (361) (344-448), CHS K2>del (449)) (121-449)], (223-214')-disulfide with L-kappa light chain humanized (1'-214') [V-KAPPA (Homo sapiens IGKV1-39*01 (86.3%) -IGKJ1*01 (100%), CDR-IMGT [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo sapiens IGKC*01 (100%) Km3 A45.1, V101 (C-KAPPA A45.1 (153'), V101 (191')) (108'-214')]; dimer (229-229'':232-232'')-bisdisulfide, produced in a cell line from Chinese hamster ovary (CHO) cells, derived from the cell line CHO-K1, glycoform alfa; substituted at the sulfur atoms of L-cysteinyl residues 223, 229, 232, 214', 223'', 229'', 232'' and 214''' with (3RS)-1-[(7S)-7-benzyl-1-{[(1R,3R)-3-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3',4':6,7]indolizino[1,2-b]quinolin-1-yl]carbamoyl}cyclobutyl]oxy}-3,6,9,12,15-pentaoxo-2,5,8,11,14-pentaazaicosan-20-yl]-2,5-dioxopyrrolidin-3-yl (pamirtecan) groups
  • Immunoglobulin G1 [de-450-lysine], anti-(human epidermal growth factor receptor HER2) (human-Mus musculus monoclonal DB-1303 γ1-chain), disulfide with human-Mus musculus monoclonal DB-1303 κ-chain, dimer, thioether with N-[6-(3-mercapto-2,5-dioxo-1-pyrrolidinyl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[[cis-3-[[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]carbonyl]cyclobutyl]oxy]methyl]glycinamide
  • immunoglobulin g1 de 450 lysine anti human epidermal growth factor receptor her2 human mus musculus monoclonal db 1303 γ1 chain disulfide with human mus musculus monoclonal db 1303 κ chain dimer thioether with n 6 3 mercapto 2 5 dioxo 1 pyrrolidinyl 1 oxohexyl glycylglycyl l phenylalanyl n cis 3 1s 9s 9 ethyl 5 fluoro 2 3 9 10 13 15 hexahydro 9 hydroxy 4 methyl 10 13 dioxo 1h 12h benzo de pyrano 3 4 6 7 indolizino 1 2 b quinolin 1 yl amino carbonyl cyclobutyl oxy methyl glycinamide
  • immunoglobulin g1 kappa anti homo sapiens erbb2 receptor tyrosine protein kinase erbb 2 epidermal growth factor receptor 2 egfr2 her2 her 2 p185c erbb2 neu cd340 humanized monoclonal antibody conjugated on an average of eight cysteinyl residues to pamirtecan comprising a linker and a camptothecin derivative exatecan
  • immunoglobulin G1-kappa, anti-[Homo sapiens ERBB2 (receptor tyrosine-protein kinase erbB-2, epidermal growth factor receptor 2, EGFR2, HER2, HER-2, p185c-erbB2, NEU, CD340)], humanized monoclonal antibody,conjugated on an average of eight cysteinyl residues to pamirtecan, comprising a linker and a camptothecin derivative (exatecan)
  • trastuzumab pamirtecan
  • Trastuzumab pamirtecan
  • trastuzumab pamirtecan [INN]
  • TRASTUZUMAB PAMIRTECAN [USAN]
  • trastuzumab pamirtecan inn
  • trastuzumab pamirtecan usan

CAS registry numbers
  • 2792722-57-5
ChEMBL ID
CHEMBL6068309
www.ebi.ac.uk
FDA ingredient codes (UNII)
  • WPL7XBK5KU

First in class
No
Orphan designation
No

Drug name stem
-mab; -mab; -tecan

Investigated indications

  • Condition
    Neoplasms
    Highest recorded phase
    2
    Condition identifier
    EFO:0000616
    Subject identifier
    D009369

  • Condition identifier
    EFO_0000616
  • Condition identifier
    MONDO_0004992
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0005070
  • Condition identifier
    MONDO_0005494
    Highest recorded phase
    1
  • Condition identifier
    MONDO_0007254
    Highest recorded phase
    3
  • Condition identifier
    MONDO_0011962
    Highest recorded phase
    3

Prodrug
No
Chirality
Single enantiomer
Inorganic
No
Natural product
No

  • Component
    Heavy chain
    Type
    Protein
    Sequence
    EVQLVESGGGLVQPGGSIRLSCAASGENIKDTYIHWVRQAPGKGLEWVARIYPTNGYTRYADSVKGRETISADTSKNTAYLQMNSLRAEDTAVYYCSRWGGDGFYAMDYWGQGTLVTVSSASTKGPSVEPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVELFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKENWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSREEMTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVESCSVMHEALHNHYTQKSLSLSPG
  • Component
    Light chain
    Type
    Protein
    Sequence
    DIQMTQSPSSLSASVGDRVTITCRASQDVNTAVAWYQQKPGKAPKLLIYSASFLYSGVPSRFSGSRSGTDFTLTISSLQPEDFATYYCQQHYTTPPTFGQGTKVEIKRTVAAPSVFIFPPSDEQLKSGTASVVCLLNNFYPREAKVQWKVDNALQSGNSQESVTEQDSKDSTYSLSSTLTLSKADYEKHKVYACEVTHQGLSSPVTKSFNRGEC
  • Component
    Glycosylation sites (N)
    Sequence
    300 $ 300''
  • Component
    Disulfide bridges
    Sequence
    22-96 $ 22''-96'' $ 23'-88' $ 23'''-88''' $ 134'-194' $ 134'''-194''' $ 147-203 $ 147''-203'' $ 223-214' $ 223''-214''' $ 229-229'' $ 232-232'' $ 264-324 $ 264''-324'' $ 370-428 $ 370''-428''

Related records

Trials (4)

In development for (1)